• Biological Signal Processing (BSP) has received FDA approval for the new version of its system HyperQ Stress System. The HyperQ Stress System is a unique PC-based ECG system that offers clinicians reliable diagnosis of ischemic heart diseases. The improvements include an updated user interface, and improved algorithms for noise reduction that improve the accuracy of diagnosis. It will also be capable of producing a diagnosis rather than just readings. The new improved version of the device is currently being tested in a pilot scheme with Maccabi Health Services. Biological Signal Processing makes non-invasive products for the diagnosis and monitoring of ischemic heart diseases.

• Cook Urology (Spencer, Indiana) introduced a full line of resection electrodes for urological procedures such as transurethral resection of the prostate (TURP) and transurethral resection of bladder tumors (TURBT). Cook offers five different types of electrodes that are compatible with all major brands of resectoscopes. The full line of electrodes enables effective prostatic or bladder tissue removal with minimal bleeding, increased visibility and decreased procedure time. Cook Urology is a division of Cook Medical. Cook Medical makes minimally invasive medical device technology for diagnostic and therapeutic procedures.

• I-Flow (Lake Forest, California) reported that an ON-Q study conducted at Miami Children's Hospital and Arnold Palmer Hospital was presented at the 2007 Pediatric Anesthesiology Meeting highlighting outcomes seen when ON-Q is used to treat pain after surgery in young heart patients. The results of the study indicate that ON-Q provides non-narcotic pain control for infants and children requiring heart surgery. Patients in the study who received the ON-Q continuous infusion pump experienced effective pain relief, used less narcotics and experienced an earlier return of bowel function sooner than patients in the control group. ON-Q is a device that consists of a small balloon pump that holds a local anesthetic and delivers it automatically through a specially designed catheter to provide even distribution of local anesthetic over a wider area, as compared to other catheters, because of its patented wicking capabilities. I-Flow makes drug delivery systems and services.

• Nanogen (San Diego) reported that it has submitted the 510(K) to the FDA for its cystic fibrosis kit and NanoChip 400 microarray system. The cystic fibrosis kit is intended to be used for carrier testing in adults of reproductive age, as an aid in newborn screening, and in confirmatory diagnostic testing in newborns and children. The genetic assay screens for 23 mutations which account for approximately 90% of cystic fibrosis cases in the U.S. Caucasian population. The NanoChip 400 instrument is an automated multiplexing platform that laboratories use to detect genetic sequences. Tests can be performed using reagents supplied by Nanogen or laboratories can develop a variety of "homebrew" assays. The NanoChip employs Nanogen's core microarray technology, which utilizes patented microfluidics and electronic technology to automate sample handling and detection of results. Nanogen produces diagnostic products.